-
1
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
2
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
15911866 10.1200/JCO.2005.04.173 1:CAS:528:DC%2BD2MXms12gs70%3D
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4265-4274
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
Chan, S.7
Grimes, D.8
Anton, A.9
Lluch, A.10
Kennedy, J.11
O'Byrne, K.12
Conte, P.13
Green, M.14
Ward, C.15
Mayne, K.16
Extra, J.M.17
-
3
-
-
84855297353
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
-
22153890 10.1016/S1470-2045(11)70336-9 1:CAS:528:DC%2BC38XkslSmsQ%3D%3D
-
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32
-
(2012)
Lancet Oncol
, vol.13
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.H.3
Roman, L.4
Tseng, L.M.5
Liu, M.C.6
Lluch, A.7
Staroslawska, E.8
De La Haba-Rodriguez, J.9
Im, S.A.10
Pedrini, J.L.11
Poirier, B.12
Morandi, P.13
Semiglazov, V.14
Srimuninnimit, V.15
Bianchi, G.16
Szado, T.17
Ratnayake, J.18
Ross, G.19
Valagussa, P.20
more..
-
4
-
-
73349115249
-
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvanttreatments of breast cancer: Final results of the FinHer Trial
-
19884557 10.1200/JCO.2008.21.4577 1:CAS:528:DC%2BC3cXhtVWisb8%3D
-
Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvanttreatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685-5692
-
(2009)
J Clin Oncol
, vol.27
, pp. 5685-5692
-
-
Joensuu, H.1
Bono, P.2
Kataja, V.3
Alanko, T.4
Kokko, R.5
Asola, R.6
Utriainen, T.7
Turpeenniemi-Hujanen, T.8
Jyrkkiö, S.9
Möykkynen, K.10
Helle, L.11
Ingalsuo, S.12
Pajunen, M.13
Huusko, M.14
Salminen, T.15
Auvinen, P.16
Leinonen, H.17
Leinonen, M.18
Isola, J.19
Kellokumpu-Lehtinen, P.L.20
more..
-
5
-
-
80052728749
-
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
-
21768458 10.1200/JCO.2011.35.0868 1:CAS:528:DC%2BC3MXhtlWisLbN
-
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373
-
(2011)
J Clin Oncol
, vol.29
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
Jeong, J.H.4
Davidson, N.E.5
Geyer, Jr.C.E.6
Martino, S.7
Mamounas, E.P.8
Kaufman, P.A.9
Wolmark, N.10
-
6
-
-
80053539103
-
Breast cancer international research group. Adjuvant trastuzumab in HER2-positive breast cancer
-
21991949 10.1056/NEJMoa0910383 1:CAS:528:DC%2BC3MXht12mtLvN
-
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Breast cancer international research group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283
-
(2011)
N Engl J Med
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.3
Pienkowski, T.4
Martin, M.5
Press, M.6
Mackey, J.7
Glaspy, J.8
Chan, A.9
Pawlicki, M.10
Pinter, T.11
Valero, V.12
Liu, M.C.13
Sauter, G.14
Von Minckwitz, G.15
Visco, F.16
Bee, V.17
Buyse, M.18
Bendahmane, B.19
Tabah-Fisch, I.20
Lindsay, M.A.21
Riva, A.22
Crown, J.23
more..
-
7
-
-
33644683395
-
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: Results of a multicenter phase II trial
-
16332965 10.1093/annonc/mdj096 1:STN:280:DC%2BD287ht1OktA%3D%3D
-
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409-414
-
(2006)
Ann Oncol
, vol.17
, pp. 409-414
-
-
Coudert, B.P.1
Arnould, L.2
Moreau, L.3
Chollet, P.4
Weber, B.5
Vanlemmens, L.6
Molucon, C.7
Tubiana, N.8
Causeret, S.9
Misset, J.L.10
Feutray, S.11
Mery-Mignard, D.12
Garnier, J.13
Fumoleau, P.14
-
8
-
-
33846297680
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
-
17200359 10.1158/1078-0432.CCR-06-1345 1:CAS:528:DC%2BD2sXotlSq
-
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233
-
(2007)
Clin Cancer Res
, vol.13
, pp. 228-233
-
-
Buzdar, A.U.1
Valero, V.2
Ibrahim, N.K.3
Francis, D.4
Broglio, K.R.5
Theriault, R.L.6
Pusztai, L.7
Green, M.C.8
Singletary, S.E.9
Hunt, K.K.10
Sahin, A.A.11
Esteva, F.12
Symmans, W.F.13
Ewer, M.S.14
Buchholz, T.A.15
Hortobagyi, G.N.16
-
9
-
-
75149145066
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort
-
20113825 10.1016/S0140-6736(09)61964-4 1:CAS:528:DC%2BC3cXht12ltLk%3D
-
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384
-
(2010)
Lancet
, vol.375
, pp. 377-384
-
-
Gianni, L.1
Eiermann, W.2
Semiglazov, V.3
Manikhas, A.4
Lluch, A.5
Tjulandin, S.6
Zambetti, M.7
Vazquez, F.8
Byakhow, M.9
Lichinitser, M.10
Climent, M.A.11
Ciruelos, E.12
Ojeda, B.13
Mansutti, M.14
Bozhok, A.15
Baronio, R.16
Feyereislova, A.17
Barton, C.18
Valagussa, P.19
Baselga, J.20
more..
-
10
-
-
77955653073
-
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
-
20480225 10.1007/s10549-010-0939-3 1:CAS:528:DC%2BC3cXnsFymu7s%3D
-
Pierga JY, Delaloge S, Espie M, Brain E, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretiere JM, Spielmann M, Savignoni A, Marty M (2010) A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 122:429-437
-
(2010)
Breast Cancer Res Treat
, vol.122
, pp. 429-437
-
-
Pierga, J.Y.1
Delaloge, S.2
Espie, M.3
Brain, E.4
Sigal-Zafrani, B.5
Mathieu, M.C.6
Bertheau, P.7
Guinebretiere, J.M.8
Spielmann, M.9
Savignoni, A.10
Marty, M.11
-
11
-
-
77951918330
-
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: Cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial
-
20177030 10.1200/JCO.2009.21.9709 1:CAS:528:DC%2BC3cXltFGhsLo%3D
-
Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl HG, Lichinitser M, Manikhas AG, Coumbos A, Kreienberg R, du Bois A, Harbeck N, Jackisch C, Müller V, Pauschinger M, Thomssen C, Lehle M, Catalani O, Lück HJ (2010) First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 28:1473-1480
-
(2010)
J Clin Oncol
, vol.28
, pp. 1473-1480
-
-
Untch, M.1
Muscholl, M.2
Tjulandin, S.3
Jonat, W.4
Meerpohl, H.G.5
Lichinitser, M.6
Manikhas, A.G.7
Coumbos, A.8
Kreienberg, R.9
Du Bois, A.10
Harbeck, N.11
Jackisch, C.12
Müller, V.13
Pauschinger, M.14
Thomssen, C.15
Lehle, M.16
Catalani, O.17
Lück, H.J.18
-
12
-
-
34548152541
-
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
-
17687157 10.1200/JCO.2007.11.0106 1:CAS:528:DC%2BD2sXhtVajsb3M
-
Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525-3533
-
(2007)
J Clin Oncol
, vol.25
, pp. 3525-3533
-
-
Telli, M.L.1
Hunt, S.A.2
Carlson, R.W.3
Guardino, A.E.4
-
13
-
-
65349101151
-
Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941
-
19411071 10.1016/j.ccr.2009.03.020 1:CAS:528:DC%2BD1MXmvVGitrg%3D
-
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3 K complex is disrupted by trastuzumab and is effectively inhibited by the PI3 K inhibitor GDC-0941. Cancer Cell 15:429-440
-
(2009)
Cancer Cell
, vol.15
, pp. 429-440
-
-
Junttila, T.T.1
Akita, R.W.2
Parsons, K.3
Fields, C.4
Lewis Phillips, G.D.5
Friedman, L.S.6
Sampath, D.7
Sliwkowski, M.X.8
-
14
-
-
31444451572
-
Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
-
16404427 10.1038/sj.bjc.6602930 1:CAS:528:DC%2BD28XmvVynsw%3D%3D
-
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267
-
(2006)
Br J Cancer
, vol.94
, pp. 259-267
-
-
Arnould, L.1
Gelly, M.2
Penault-Llorca, F.3
Benoit, L.4
Bonnetain, F.5
Migeon, C.6
Cabaret, V.7
Fermeaux, V.8
Bertheau, P.9
Garnier, J.10
Jeannin, J.F.11
Coudert, B.12
-
15
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
12975461 10.1200/JCO.2003.05.013 1:CAS:528:DC%2BD2cXpsVajsb8%3D
-
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947
-
(2003)
J Clin Oncol
, vol.21
, Issue.21
, pp. 3940-3947
-
-
Weng, W.K.1
Levy, R.2
-
16
-
-
78751524881
-
Interindividual variability of response to rituximab: From biological origins to individualized therapies
-
21208903 10.1158/1078-0432.CCR-10-1292 1:CAS:528:DC%2BC3MXhtVemsg%3D%3D
-
Cartron G, Trappe RU, Solal-Céligny P, Hallek M (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 17:19-30
-
(2011)
Clin Cancer Res
, vol.17
, pp. 19-30
-
-
Cartron, G.1
Trappe, R.U.2
Solal-Céligny, P.3
Hallek, M.4
-
17
-
-
0036464719
-
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
-
11806974 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D
-
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
-
(2002)
Blood
, vol.99
, pp. 754-758
-
-
Cartron, G.1
Dacheux, L.2
Salles, G.3
Solal-Celigny, P.4
Bardos, P.5
Colombat, P.6
Watier, H.7
-
18
-
-
34548179576
-
Role of the HER2 [Ile655 Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
-
17693647 10.1093/annonc/mdm181 1:STN:280:DC%2BD2svnsFSjtQ%3D%3D
-
Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pages G, Milano G (2007) Role of the HER2 [Ile655 Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 18:1335-1341
-
(2007)
Ann Oncol
, vol.18
, pp. 1335-1341
-
-
Beauclair, S.1
Formento, P.2
Fischel, J.L.3
Lescaut, W.4
Largillier, R.5
Chamorey, E.6
Hofman, P.7
Ferrero, J.M.8
Pages, G.9
Milano, G.10
-
19
-
-
42949157368
-
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
-
18347005 10.1200/JCO.2007.14.8957 1:CAS:528:DC%2BD1cXmsFemsLg%3D
-
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796
-
(2008)
J Clin Oncol
, vol.26
, pp. 1789-1796
-
-
Musolino, A.1
Naldi, N.2
Bortesi, B.3
Pezzuolo, D.4
Capelletti, M.5
Missale, G.6
Laccabue, D.7
Zerbini, A.8
Camisa, R.9
Bisagni, G.10
Neri, T.M.11
Ardizzoni, A.12
-
20
-
-
79957874790
-
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
-
21109570 10.1093/annonc/mdq585 1:STN:280:DC%2BC3MrkvFOntQ%3D%3D
-
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y (2011) FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 22:1302-1307
-
(2011)
Ann Oncol
, vol.22
, pp. 1302-1307
-
-
Tamura, K.1
Shimizu, C.2
Hojo, T.3
Akashi-Tanaka, S.4
Kinoshita, T.5
Yonemori, K.6
Kouno, T.7
Katsumata, N.8
Ando, M.9
Aogi, K.10
Koizumi, F.11
Nishio, K.12
Fujiwara, Y.13
-
21
-
-
84862522354
-
Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients
-
22504044 10.1158/1078-0432.CCR-11-2294 1:CAS:528:DC%2BC38Xos1OksLk%3D
-
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM (2012) Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 18:3478-3786
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3478-3786
-
-
Hurvitz, S.A.1
Betting, D.J.2
Stern, H.M.3
Quinaux, E.4
Stinson, J.5
Seshagiri, S.6
Zhao, Y.7
Buyse, M.8
Mackey, J.9
Driga, A.10
Damaraju, S.11
Sliwkowski, M.X.12
Robert, N.J.13
Valero, V.14
Crown, J.15
Falkson, C.16
Brufsky, A.17
Pienkowski, T.18
Eiermann, W.19
Martin, M.20
Bee, V.21
Marathe, O.22
Slamon, D.J.23
Timmerman, J.M.24
more..
-
22
-
-
84866646922
-
Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
-
23028798 10.1371/journal.pone.0045127 1:CAS:528:DC%2BC38XhsVaktr7M
-
Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J (2012) Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One 7:e45127
-
(2012)
PLoS One
, vol.7
, pp. 45127
-
-
Jung, M.1
Koo, J.S.2
Moon, Y.W.3
Park, B.W.4
Kim, S.I.5
Park, S.6
Lee, S.H.7
Hong, S.8
Rha, S.Y.9
Chung, H.C.10
Kim, J.H.11
Sohn, J.12
-
23
-
-
84865054217
-
ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy
-
22906996 10.1159/000341359 1:CAS:528:DC%2BC38Xht12nu7rE
-
Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ (2012) ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 83:218-227
-
(2012)
Oncology
, vol.83
, pp. 218-227
-
-
Kim, J.W.1
Kim, J.H.2
Im, S.A.3
Kim, Y.J.4
Han, H.S.5
Kim, J.S.6
Han, S.W.7
Jeon, Y.K.8
Oh, D.Y.9
Han, W.10
Kim, T.Y.11
Park, I.A.12
Noh, D.Y.13
Bang, Y.J.14
-
24
-
-
74949141693
-
Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial
-
19917839 10.1200/JCO.2009.23.0946 1:CAS:528:DC%2BC3cXht1agsLc%3D
-
Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134
-
(2009)
J Clin Oncol
, vol.27
, pp. 6129-6134
-
-
Spielmann, M.1
Roche, H.2
Delozier, T.3
Canon, J.L.4
Romieu, G.5
Bourgeois, H.6
Extra, J.M.7
Serin, D.8
Kerbrat, P.9
Machiels, J.P.10
Lortholary, A.11
Orfeuvre, H.12
Campone, M.13
Hardy-Bessard, A.C.14
Coudert, B.15
Maerevoet, M.16
Piot, G.17
Kramar, A.18
Martin, A.L.19
Penault-Llorca, F.20
more..
-
25
-
-
0034680102
-
Molecular portraits of human breast tumours
-
10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
-
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
-
(2000)
Nature
, vol.406
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
Van De Rijn, M.4
Jeffrey, S.S.5
Rees, C.A.6
Pollack, J.R.7
Ross, D.T.8
Johnsen, H.9
Akslen, L.A.10
Fluge, O.11
Pergamenschikov, A.12
Williams, C.13
Zhu, S.X.14
Lønning, P.E.15
Børresen-Dale, A.L.16
Brown, P.O.17
Botstein, D.18
-
26
-
-
81555216077
-
Gene expression profiling in breast cancer: Classification, prognostication, and prediction
-
22098854 10.1016/S0140-6736(11)61539-0 1:CAS:528:DC%2BC3MXhsVyrs7nE
-
Reis-Filho JS, Pusztai L (2011) Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378:1812-1823
-
(2011)
Lancet
, vol.378
, pp. 1812-1823
-
-
Reis-Filho, J.S.1
Pusztai, L.2
-
27
-
-
60849097255
-
Gene-expression signatures in breast cancer
-
19228622 10.1056/NEJMra0801289 1:CAS:528:DC%2BD1MXitFWqs70%3D
-
Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
-
(2009)
N Engl J Med
, vol.360
, pp. 790-800
-
-
Sotiriou, C.1
Pusztai, L.2
-
28
-
-
0022600388
-
The neu oncogene encodes an epidermal growth factor receptor-related protein
-
3945311 10.1038/319226a0 1:CAS:528:DyaL28XhtVensLk%3D
-
Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230
-
(1986)
Nature
, vol.319
, pp. 226-230
-
-
Bargmann, C.I.1
Hung, M.C.2
Weinberg, R.A.3
-
29
-
-
0032078876
-
ERBB2 oncogene in human breast cancer and its clinical significance
-
9797688 10.1016/S0959-8049(97)10157-5 1:STN:280:DyaK1M%2FhsVChsA%3D%3D
-
Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808
-
(1998)
Eur J Cancer
, vol.34
, pp. 791-808
-
-
Revillion, F.1
Bonneterre, J.2
Peyrat, J.P.3
-
30
-
-
34548531901
-
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
-
10.1200/JCO.2006.09.1611 1:CAS:528:DC%2BD2sXhtFanu7zE
-
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. JClin Oncol 25:3859-3865
-
(2007)
JClin Oncol
, vol.25
, pp. 3859-3865
-
-
Suter, T.M.1
Procter, M.2
Van Veldhuisen, D.J.3
Muscholl, M.4
Bergh, J.5
Carlomagno, C.6
Perren, T.7
Passalacqua, R.8
Bighin, C.9
Klijn, J.G.10
Ageev, F.T.11
Hitre, E.12
Groetz, J.13
Iwata, H.14
Knap, M.15
Gnant, M.16
Muehlbauer, S.17
Spence, A.18
Gelber, R.D.19
Piccart-Gebhart, M.J.20
more..
-
31
-
-
81055140610
-
Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: A systematic review and meta-analysis
-
21474413 10.1016/j.canep.2011.01.007 1:CAS:528:DC%2BC3MXhsVOks73P
-
Dahabreh IJ, Murray S (2011) Lack of replication for the association between HER2 I655V polymorphism and breast cancer risk: a systematic review and meta-analysis. Cancer Epidemiol 35:503-509
-
(2011)
Cancer Epidemiol
, vol.35
, pp. 503-509
-
-
Dahabreh, I.J.1
Murray, S.2
-
32
-
-
78651076978
-
Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: Meta-analysis of 22 studies involving 19,341 subjects
-
20524057 10.1007/s10549-010-0965-1 1:CAS:528:DC%2BC3cXhsFWgtL%2FO
-
Ma Y, Yang J, Zhang P, Liu Z, Yang Z, Qin H (2011) Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects. Breast Cancer Res Treat 125:237-241
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 237-241
-
-
Ma, Y.1
Yang, J.2
Zhang, P.3
Liu, Z.4
Yang, Z.5
Qin, H.6
-
33
-
-
0034163421
-
Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
-
10699071 10.1093/jnci/92.5.412 1:CAS:528:DC%2BD3cXhvFGhu70%3D
-
Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 412-417
-
-
Xie, D.1
Shu, X.O.2
Deng, Z.3
Wen, W.Q.4
Creek, K.E.5
Dai, Q.6
Gao, Y.T.7
Jin, F.8
Zheng, W.9
-
34
-
-
18744378545
-
A putative molecular-activation switch in the transmembrane domain of erbB2
-
12461170 10.1073/pnas.252640799 1:CAS:528:DC%2BD38Xps1egurk%3D
-
Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 99:15937-15940
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 15937-15940
-
-
Fleishman, S.J.1
Schlessinger, J.2
Ben-Tal, N.3
-
35
-
-
84865453635
-
Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody
-
22794164 10.1021/ac301426h 1:CAS:528:DC%2BC38XhtVSqtrvN
-
Zhang T, Zhang J, Hewitt D, Tran B, Gao X, Qiu ZJ, Tejada M, Gazzano-Santoro H, Kao YH (2012) Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody. Anal Chem 84:7112-7123
-
(2012)
Anal Chem
, vol.84
, pp. 7112-7123
-
-
Zhang, T.1
Zhang, J.2
Hewitt, D.3
Tran, B.4
Gao, X.5
Qiu, Z.J.6
Tejada, M.7
Gazzano-Santoro, H.8
Kao, Y.H.9
-
36
-
-
0034076307
-
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
-
10742152 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D
-
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
37
-
-
0034772498
-
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells
-
11592078 10.1002/1521-4141(2001010)31:10<3016: AID-IMMU3016>3.0. CO;2-J 1:CAS:528:DC%2BD3MXnvFSgtb4%3D
-
Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA (2001) Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31:3016-3025
-
(2001)
Eur J Immunol
, vol.31
, pp. 3016-3025
-
-
Carson, W.E.1
Parihar, R.2
Lindemann, M.J.3
Personeni, N.4
Dierksheide, J.5
Meropol, N.J.6
Baselga, J.7
Caligiuri, M.A.8
-
38
-
-
0030611089
-
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
-
9276722 10.1172/JCI119616 1:CAS:528:DyaK2sXlvFOgs7k%3D
-
Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP (1997) A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 100:1059-1070
-
(1997)
J Clin Invest
, vol.100
, pp. 1059-1070
-
-
Wu, J.1
Edberg, J.C.2
Redecha, P.B.3
Bansal, V.4
Guyre, P.M.5
Coleman, K.6
Salmon, J.E.7
Kimberly, R.P.8
-
39
-
-
27144497346
-
Singleagent rituximab in patients with follicular ormantle cell lymphoma: Clinical and biological factors that are predictive of response and event free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK)
-
16030029 10.1093/annonc/mdi320 1:STN:280:DC%2BD2MvpvFKitA%3D%3D
-
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF (2005) Singleagent rituximab in patients with follicular ormantle cell lymphoma: clinical and biological factors that are predictive of response and event free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16:1675-1682
-
(2005)
Ann Oncol
, vol.16
, pp. 1675-1682
-
-
Ghielmini, M.1
Rufibach, K.2
Salles, G.3
Leoncini-Franscini, L.4
Léger-Falandry, C.5
Cogliatti, S.6
Fey, M.7
Martinelli, G.8
Stahel, R.9
Lohri, A.10
Ketterer, N.11
Wernli, M.12
Cerny, T.13
Schmitz, S.F.14
-
40
-
-
84862123411
-
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
-
22271896 10.3324/haematol.2011.050419
-
Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97:937-994
-
(2012)
Haematologica
, vol.97
, pp. 937-994
-
-
Goldman, B.H.1
Braziel, R.M.2
Fisher, R.I.3
Leblanc, M.4
Maloney, D.G.5
Press, O.W.6
Miller, T.P.7
Rimsza, L.M.8
-
41
-
-
34548509226
-
FCGR2A and FCGR3A polymorp hisms associated with clinical outcome of epiderman growth factor receptor expressing metastatic colorectalpatients treated with single agent cetuximab
-
10.1200/JCO.2006.08.8021
-
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ (2007) FCGR2A and FCGR3A polymorp hisms associated with clinical outcome of epiderman growth factor receptor expressing metastatic colorectalpatients treated with single agent cetuximab. J Clin Oncol 24:3712-3718
-
(2007)
J Clin Oncol
, vol.24
, pp. 3712-3718
-
-
Zhang, W.1
Gordon, M.2
Schultheis, A.M.3
Yang, D.Y.4
Nagashima, F.5
Azuma, M.6
Chang, H.M.7
Borucka8
Lurje, G.9
Sherrod, A.E.10
Iqbal, S.11
Groshen, S.12
Lenz, H.J.13
-
42
-
-
84866863976
-
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
-
22885164 10.1182/blood-2012-05-431825
-
Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G (2012) Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120:2650-2657
-
(2012)
Blood
, vol.120
, pp. 2650-2657
-
-
Ghesquières, H.1
Cartron, G.2
Seymour, J.F.3
Delfau-Larue, M.H.4
Offner, F.5
Soubeyran, P.6
Perrot, A.7
Brice, P.8
Bouabdallah, R.9
Sonet, A.10
Dupuis, J.11
Casasnovas, O.12
Catalano, J.V.13
Delmer, A.14
Jardin, F.15
Verney, A.16
Dartigues, P.17
Salles, G.18
-
43
-
-
56749096598
-
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
-
18955438 10.1200/JCO.2008.19.4118 author reply 5491- 5482
-
Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M (2008) Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 26:5489-5491 author reply 5491- 5482
-
(2008)
J Clin Oncol
, vol.26
, pp. 5489-5491
-
-
Lejeune, J.1
Thibault, G.2
Ternant, D.3
Cartron, G.4
Watier, H.5
Ohresser, M.6
|